News

Rodney Rohde, PhD, SM(ASCP), SVCM, MBCM, FACSc, discusses the ongoing concerns about the federal government’s hold on funding for research and the potential chilling effect that it may have on laboratory professionals and deciding on careers, especially in areas such as public health. He also talks about locating and engaging in potential alternative resources for research funding.

New longitudinal study findings suggest booster vaccination may not be necessary despite declining antibody levels.

In our latest podcast, Tim Gauthier, PharmD, BCPS, BCIDP, discusses all things pathogens and antibiotics. He also details the opportunities presented for antimicrobial stewardship when it combines diagnostics and treatment duration.

Application of GBD methods reveals substantial RSV-attributable hospitalizations and informs vaccine and surveillance strategies.

At ASM Microbe 2025, Meghan Starolis, PhD, discusses her presentation on antiviral testing including the advantages and limitations to genotypic and phenotypic testing and looking at how this can affect the immunocompromised population.

Single-dose, nonvaccine antiviral shows significant seasonal prophylactic efficacy and favorable safety profile in over 5000 healthy adults.

American Society for Microbiology (ASM) CEO Stefano Bertuzzi, PhD, MPH, talks about ASM's comprehensive scientific program, the networking opportunities at the meeting, and the unique format ASM plans to roll out for the 2026 conference.

In a wide-ranging interview, Susan Weiss, PhD, talks about winning the ASM Lifetime Achievement award, her work on coronaviruses, and her concerns around federal government funding and how it may shake up and limit basic science research.

At ASM Microbe 2025, a Puerto Rico study linked increased fungal spore concentrations to rises in viral respiratory infections, suggesting potential early warning utility.

At ASM Microbe 2025, a cross-sectional study highlighted Burkholderia cepacia dominance, widespread antibiotic resistance, and key risk factors, including invasive device use and patient demographics.

At the ASM Microbe conference, Mike Bromley, PhD, offers some insights on the importance of a One Health approach addressing the growing antifungal resistance to azoles and Aspergillus fumigatus because of the connection between crop spraying and the rise of resistance.

At ASM Microbe 2025, researchers underscored the role of NAAT in outpatient CDI diagnosis and raised concerns over PPI-related risk in older, health care–associated cases.

A study presented at ASM Microbe 2025 questions the clinical value of adding enzyme immunoassays to PCR-based CDI diagnostics amid sensitivity concerns.

Presented at ASM Microbe 2025, a bioinformatics study highlights 9 human miRNAs capable of binding and potentially inhibiting both hepatitis C and bovine viral diarrhea viruses.

Gilead’s Yeztugo, a long-acting HIV capsid inhibitor, shows 96 to 100% efficacy in phase 3 trials and aims to expand access worldwide through regulatory filings and support programs.

A ValuePenguin poll of more than 2000 adults highlights partisan divides, persistent myths, and concerns over vaccine access, with 41% fearing skepticism could hinder immunization efforts.

Ep 1, Part 3 of 4 with Robert Bransfield, MD, explores treatment-resistant mental health issues linked to infection history and diverse progression patterns.

Data from the 2023 Centers for Disease Control and Prevention surveillance report highlight key differences in death rates across states and populations, informing targeted public health efforts.

After initially closing its viral hepatitis and sexually transmitted disease laboratories, the CDC rescinds staff terminations, preserving vital disease surveillance and outbreak response capabilities.

Study findings underscore value of obtaining sputum culture prior to initiating antibiotics for greater detection of pathogens without opportunistic bacteria of uncertain clinical relevance.

Evaluating safety and efficacy against symptomatic, virologically confirmed dengue in children and adolescents.

In an early release of his letter for the Summer issue, Editor-in-Chief Jason Gallagher, PharmD, FCCP, FIDP, FIDSA, BCPS, discusses the recent changes to the Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices (ACIP), and where professional societies must step in and lead with research data and clinical guidance in the absence of experienced committee members.

Successful HCV treatment with DAAs was associated with reduced risks of CKD, stroke, major adverse cardiac events, and neurocognitive disorders.

Jatin Vyas, PhD, MD, offers some insights into the economics of development, the biology of fungal species, and the difficulties behind creating new antifungal molecules.

This week, the FDA expanded Moderna’s RSV vaccine to younger at-risk adults, Merck’s Enflonsia received approval to protect infants from RSV, HHS Secretary RFK Jr replaced the CDC’s ACIP, and more.

The antiviral, glecaprevir/pibrentasvir (Mavyet), is the first and only oral 8-week pangenotypic treatment approved for people with acute or chronic hepatitis C. The approval supports global clinical guidelines to advance testing and treatment of HCV regardless of chronicity and supports public health goals for disease elimination.

Innoviva and GARDP's breakthrough treatment could become the first new gonorrhea antibiotic in decades amid rising antimicrobial resistance.

The federal agency approved the company’s mRNA-1345 (mRESVIA) vaccine for people who are between the ages of 18 to 59 years.